Rajiv P Parikh1,2,3, Elizabeth B Odom4,5, Liyang Yu5, Graham A Colditz5, Terence M Myckatyn4. 1. Division of Plastic and Reconstructive Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA. parikhr@wudosis.wustl.edu. 2. Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA. parikhr@wudosis.wustl.edu. 3. Division of Plastic and Reconstructive Surgery, Department of Surgery, Washington University School of Medicine, 660 S. Euclid Ave, Suite 1150 NW Tower, Box 8238, St. Louis, MO, 63110, USA. parikhr@wudosis.wustl.edu. 4. Division of Plastic and Reconstructive Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA. 5. Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Abstract
PURPOSE: Tamoxifen therapy is integral in the treatment of patients with hormone receptor-positive breast cancer. However, there is an association between tamoxifen and thromboembolic events. Flap and systemic thromboembolic events have devastating consequences in microvascular breast reconstruction. Currently, there are conflicting data on the association between tamoxifen therapy and thromboembolic complications for patients undergoing microvascular breast reconstruction. The objective of this study is to determine if perioperative tamoxifen therapy modifies the risk of complications and thromboembolic events for patients with breast cancer undergoing microvascular breast reconstruction. METHODS: A comprehensive literature search was performed across six databases from January 2003 to February 2016. Pooled estimates and relative risk (RR) were calculated using a random-effects model, confounding was examined with meta-regression, and risk of bias was evaluated. Primary outcomes were thrombotic flap complications and total flap loss. Study quality was assessed using Downs and Black criteria. RESULTS: Of 95 studies reviewed, 4 studies comprising 1700 patients and 2245 procedures were included for analysis. Compared to non-recipients, patients on tamoxifen were at increased risk of developing thrombotic flap complications (pooled RR 1.5; 95% CI 1.14-1.98) and total flap loss (pooled RR 3.35; 95% CI 0.95-11.91). There was no significant heterogeneity present in either outcome and no evidence of publication bias. CONCLUSIONS: Perioperative tamoxifen therapy may increase the risk of thrombotic flap complications and flap loss for patients with breast cancer undergoing microvascular reconstruction. These findings further the ability of providers to make evidence-based recommendations in the perioperative management of patients with breast cancer.
PURPOSE:Tamoxifen therapy is integral in the treatment of patients with hormone receptor-positive breast cancer. However, there is an association between tamoxifen and thromboembolic events. Flap and systemic thromboembolic events have devastating consequences in microvascular breast reconstruction. Currently, there are conflicting data on the association between tamoxifen therapy and thromboembolic complications for patients undergoing microvascular breast reconstruction. The objective of this study is to determine if perioperative tamoxifen therapy modifies the risk of complications and thromboembolic events for patients with breast cancer undergoing microvascular breast reconstruction. METHODS: A comprehensive literature search was performed across six databases from January 2003 to February 2016. Pooled estimates and relative risk (RR) were calculated using a random-effects model, confounding was examined with meta-regression, and risk of bias was evaluated. Primary outcomes were thrombotic flap complications and total flap loss. Study quality was assessed using Downs and Black criteria. RESULTS: Of 95 studies reviewed, 4 studies comprising 1700 patients and 2245 procedures were included for analysis. Compared to non-recipients, patients on tamoxifen were at increased risk of developing thrombotic flap complications (pooled RR 1.5; 95% CI 1.14-1.98) and total flap loss (pooled RR 3.35; 95% CI 0.95-11.91). There was no significant heterogeneity present in either outcome and no evidence of publication bias. CONCLUSIONS: Perioperative tamoxifen therapy may increase the risk of thrombotic flap complications and flap loss for patients with breast cancer undergoing microvascular reconstruction. These findings further the ability of providers to make evidence-based recommendations in the perioperative management of patients with breast cancer.
Entities:
Keywords:
Breast cancer; Breast reconstruction; Selective estrogen receptor modulator; Tamoxifen; Thromboembolism
Authors: Monica Morrow; Yun Li; Amy K Alderman; Reshma Jagsi; Ann S Hamilton; John J Graff; Sarah T Hawley; Steven J Katz Journal: JAMA Surg Date: 2014-10 Impact factor: 14.766
Authors: A Howell; J Cuzick; M Baum; A Buzdar; M Dowsett; J F Forbes; G Hoctin-Boes; J Houghton; G Y Locker; J S Tobias Journal: Lancet Date: 2005 Jan 1-7 Impact factor: 79.321
Authors: M E T Tesselaar; F P H T M Romijn; I K Van Der Linden; F A Prins; R M Bertina; S Osanto Journal: J Thromb Haemost Date: 2006-12-13 Impact factor: 5.824
Authors: Michael D Johnson; Hong Zuo; Kyung-Hoon Lee; Joseph P Trebley; James Michael Rae; Ross V Weatherman; Zeruesanay Desta; David A Flockhart; Todd C Skaar Journal: Breast Cancer Res Treat Date: 2004-05 Impact factor: 4.872
Authors: Yassir Eltahir; Lisanne L C H Werners; Marieke M Dreise; Ingeborg A Zeijlmans van Emmichoven; Liesbeth Jansen; Paul M N Werker; Geertruida H de Bock Journal: Plast Reconstr Surg Date: 2013-08 Impact factor: 4.730
Authors: Harold J Burstein; Christina Lacchetti; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen E Gelmon; Sharon H Giordano; Clifford A Hudis; Alexander J Solky; Vered Stearns; Eric P Winer; Jennifer J Griggs Journal: J Clin Oncol Date: 2016-02-16 Impact factor: 44.544
Authors: Kevin M Blum; Lauren C Roby; Jacob C Zbinden; Yu-Chun Chang; Gabriel J M Mirhaidari; James W Reinhardt; Tai Yi; Jenny C Barker; Christopher K Breuer Journal: Sci Rep Date: 2021-04-13 Impact factor: 4.379
Authors: Mohammadhossein Mirzaei; Seyed Amir Sheikholeslami; Arsalan Jalili; Ahmad Bereimipour; Sheida Sharbati; Vahid Kaveh; Sina Salari Journal: J Med Life Date: 2022-06
Authors: Felipe Cavagna; Anagloria Pontes; Mario Cavagna; Artur Dzik; Nilka F Donadio; Rafael Portela; Michelle T Nagai; Luiz H Gebrim Journal: Contemp Oncol (Pozn) Date: 2017-12-30
Authors: Michał Gontarz; Jakub Bargiel; Krzysztof Gąsiorowski; Tomasz Marecik; Paweł Szczurowski; Jan Zapała; Grażyna Wyszyńska-Pawelec Journal: World J Surg Oncol Date: 2022-03-12 Impact factor: 2.754